Details of the Drug
General Information of Drug (ID: DM1ZPGY)
Drug Name |
N-phenethylquinoxaline-2-carboxamide
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
N-phenethylquinoxaline-2-carboxamide; CHEMBL245820; N-(2-phenylethyl)quinoxaline-2-carboxamide; N-(2-phenylethyl)-2-quinoxalinecarboxamide; 2-quinoxalinecarboxamide, N-(2-phenylethyl)-; AC1NRYO0; MLS001198127; SCHEMBL7453913; VCRCXANKNYQHIW-UHFFFAOYSA-N; MolPort-002-738-788; HMS2868E05; ZINC4744930; STK783123; BDBM50197271; AKOS001338925; MCULE-6665471272; N~2~-phenethyl-2-quinoxalinecarboxamide; KB-55566; SMR000559426; ST4122831; N-(2-phenylethyl)quinoxalin-2-ylcarboxamide
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 277.32 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 3.3 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 4 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 1 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 3 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||||||||